دورية أكاديمية
أعرض في EDS

Association of PD-L1 expression with driver gene mutations and clinicopathological characteristics in non-small cell lung cancer: A real-world study of 10 441 patients.

التفاصيل البيبلوغرافية
العنوان: Association of PD-L1 expression with driver gene mutations and clinicopathological characteristics in non-small cell lung cancer: A real-world study of 10 441 patients.
المؤلفون: Ruiz G; Pathology & Molecular Biology Laboratories, Biomakers, Buenos Aires, Argentina., Enrico D; Thoracic Oncology Unit, Department of Medical Oncology, Alexander Fleming Cancer Institute, Buenos Aires, Argentina.; Clinical Research Unit, Department of Medical Oncology, Alexander Fleming Cancer Institute, Buenos Aires, Argentina., Mahmoud YD; Universidad Argentina de la Empresa (UADE), Instituto de Tecnología (INTEC), Buenos Aires, Argentina.; Laboratorio de Glicomedicina, Instituto de Biología y Medicina Experimental (IBYME), Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Buenos Aires, Argentina., Ruiz A; Pathology & Molecular Biology Laboratories, Biomakers, Buenos Aires, Argentina., Cantarella MF; Pathology & Molecular Biology Laboratories, Biomakers, Buenos Aires, Argentina., Leguina L; Pathology & Molecular Biology Laboratories, Biomakers, Buenos Aires, Argentina., Barberis M; Pathology & Molecular Biology Laboratories, Biomakers, Buenos Aires, Argentina., Beña A; Pathology & Molecular Biology Laboratories, Biomakers, Buenos Aires, Argentina., Brest E; Pathology & Molecular Biology Laboratories, Biomakers, Buenos Aires, Argentina., Starapoli S; Pathology & Molecular Biology Laboratories, Biomakers, Buenos Aires, Argentina., Mendoza Bertelli A; Pathology & Molecular Biology Laboratories, Biomakers, Buenos Aires, Argentina., Tsou F; Thoracic Oncology Unit, Department of Medical Oncology, Alexander Fleming Cancer Institute, Buenos Aires, Argentina.; Clinical Research Unit, Department of Medical Oncology, Alexander Fleming Cancer Institute, Buenos Aires, Argentina., Pupareli C; Thoracic Oncology Unit, Department of Medical Oncology, Alexander Fleming Cancer Institute, Buenos Aires, Argentina.; Clinical Research Unit, Department of Medical Oncology, Alexander Fleming Cancer Institute, Buenos Aires, Argentina., Coppola MP; Medical Oncology Unit, Hospital Zonal Especializado en Agudos y Crónicos Dr. Antonio Cetrangolo, Buenos Aires, Argentina., Scocimarro A; Medical Oncology Unit, Hospital Zonal Especializado en Agudos y Crónicos Dr. Antonio Cetrangolo, Buenos Aires, Argentina., Sena S; Medical Oncology Department, Hospital Alemán, Buenos Aires, Argentina., Levit P; Medical Oncology Unit, Unión Personal-Accord Salud, Buenos Aires, Argentina., Perfetti A; Medical Oncology Unit, Unión Personal-Accord Salud, Buenos Aires, Argentina.; Medical Oncology Department, Centro de Educación Médica e Investigaciones Clínicas (CEMIC), Buenos Aires, Argentina., Aman E; Medical Oncology Unit, Swiss Medical Group, Buenos Aires, Argentina., Girotti MR; Pathology & Molecular Biology Laboratories, Biomakers, Buenos Aires, Argentina.; Universidad Argentina de la Empresa (UADE), Instituto de Tecnología (INTEC), Buenos Aires, Argentina., Arrieta O; Head of Thoracic Oncology Unit, Unidad Funcional de Oncología Torácica, Instituto Nacional de Cancerología (INCan), Mexico City, Mexico., Martín C; Thoracic Oncology Unit, Department of Medical Oncology, Alexander Fleming Cancer Institute, Buenos Aires, Argentina.; Clinical Research Unit, Department of Medical Oncology, Alexander Fleming Cancer Institute, Buenos Aires, Argentina., Salanova R; Pathology & Molecular Biology Laboratories, Biomakers, Buenos Aires, Argentina.
المصدر: Thoracic cancer [Thorac Cancer] 2024 Apr; Vol. 15 (11), pp. 895-905. Date of Electronic Publication: 2024 Mar 08.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Wiley Publishing Asia Pty Ltd Country of Publication: Singapore NLM ID: 101531441 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1759-7714 (Electronic) Linking ISSN: 17597706 NLM ISO Abbreviation: Thorac Cancer Subsets: MEDLINE
أسماء مطبوعة: Publication: November 2012- : Singapore : Tianjin : Wiley Publishing Asia Pty Ltd ; Tianjin Lung Cancer Institute
Original Publication: Richmond, Vic. : Tianjin : Blackwell Pub. Asia Pty Ltd. ; Tianjin Lung Cancer Institute
مواضيع طبية MeSH: Carcinoma, Non-Small-Cell Lung*/pathology , Lung Neoplasms*/pathology , Adenocarcinoma*/genetics, Male ; Humans ; Protein-Tyrosine Kinases/genetics ; B7-H1 Antigen/genetics ; B7-H1 Antigen/metabolism ; Retrospective Studies ; Anaplastic Lymphoma Kinase/genetics ; Proto-Oncogene Proteins/genetics ; Mutation ; ErbB Receptors/genetics
مستخلص: Background: Programmed death ligand-1 (PD-L1) expression is a well-known predictive biomarker of response to immune checkpoint blockade in non-small cell lung cancer (NSCLC). However, there is limited evidence of the relationship between PD-L1 expression, clinicopathological features, and their association with major driver mutations in NSCLC patients in Latin America.
Methods: This retrospective study included patients from Argentina with advanced NSCLC, and centralized evaluation of PD-L1 expression concurrently with genomic alterations in the driver genes EGFR, ALK, ROS1, BRAF, and/or KRAS G12C in FFPE tissue samples.
Results: A total of 10 441 patients with advanced NSCLC were analyzed. Adenocarcinoma was the most frequent histological subtype (71.1%). PD-L1 expression was categorized as PD-L1 negative (45.1%), PD-L1 positive low-expression 1%-49% (32.3%), and PD-L1 positive high-expression ≥50% (22.6%). Notably, current smokers and males were more likely to have tumors with PD-L1 tumor proportion score (TPS) ≥50% and ≥ 80% expression, respectively (p < 0.001 and p = 0.013). Tumors with non-adenocarcinoma histology had a significantly higher median PD-L1 expression (p < 0.001). Additionally, PD-L1 in distant nodes was more likely ≥50% (OR 1.60 [95% CI: 1.14-2.25, p < 0.01]). In the multivariate analysis, EGFR-positive tumors were more commonly associated with PD-L1 low expression (OR 0.62 [95% CI: 0.51-0.75], p < 0.01), while ALK-positive tumors had a significant risk of being PD-L1 positive (OR 1.81 [95% CI: 1.30-2.52], p < 0.01).
Conclusions: PD-L1 expression was associated with well-defined clinicopathological and genomic features. These findings provide a comprehensive view of the expression of PD-L1 in patients with advanced NSCLC in a large Latin American cohort.
(© 2024 The Authors. Thoracic Cancer published by John Wiley & Sons Australia, Ltd.)
References: Cancer Res. 2016 Jan 15;76(2):227-38. (PMID: 26637667)
Sci Rep. 2017 Aug 31;7(1):10255. (PMID: 28860576)
PLoS One. 2022 Aug 18;17(8):e0273207. (PMID: 35980949)
Transl Lung Cancer Res. 2019 Aug;8(4):429-449. (PMID: 31555517)
Thorac Cancer. 2022 Dec;13(23):3362-3373. (PMID: 36317227)
J Clin Pathol. 2018 Mar;71(3):189-194. (PMID: 29097600)
Ann Oncol. 2019 Oct 1;30(10):1653-1659. (PMID: 31435660)
JAMA Netw Open. 2022 May 2;5(5):e2214046. (PMID: 35612853)
Int J Mol Sci. 2019 Feb 14;20(4):. (PMID: 30769852)
Thorac Cancer. 2024 Apr;15(11):895-905. (PMID: 38456253)
Cancer Biol Med. 2019 Nov;16(4):811-821. (PMID: 31908897)
Lung Cancer. 2016 Sep;99:79-87. (PMID: 27565919)
J Thorac Oncol. 2015 Dec;10(12):1726-35. (PMID: 26473645)
PLoS One. 2016 Nov 15;11(11):e0166626. (PMID: 27846317)
Oncoimmunology. 2015 Dec 21;5(3):e1094598. (PMID: 27141355)
Lancet Oncol. 2021 Feb;22(2):198-211. (PMID: 33476593)
Clin Lung Cancer. 2016 Jul;17(4):263-270.e2. (PMID: 26707383)
Cancers (Basel). 2018 Jul 27;10(8):. (PMID: 30060457)
Ann Oncol. 2020 Jun;31(6):807-814. (PMID: 32171752)
J Immunol. 2009 Mar 1;182(5):3294-303. (PMID: 19234228)
Clin Cancer Res. 2015 Sep 1;21(17):4014-21. (PMID: 26019170)
Oncologist. 2021 Jul;26(7):e1226-e1239. (PMID: 33829580)
Biochim Biophys Acta. 2007 Aug;1773(8):1263-84. (PMID: 17126425)
J Clin Oncol. 2012 Mar 10;30(8):863-70. (PMID: 22215748)
Transl Lung Cancer Res. 2019 Aug;8(4):413-428. (PMID: 31555516)
ESMO Open. 2021 Oct;6(5):100251. (PMID: 34455288)
N Engl J Med. 2016 Nov 10;375(19):1823-1833. (PMID: 27718847)
Trends Cancer. 2021 May;7(5):410-429. (PMID: 33309239)
Virchows Arch. 2020 Aug;477(2):207-217. (PMID: 31989260)
Oncotarget. 2018 Jan 05;9(7):7684-7699. (PMID: 29484144)
Lung Cancer. 2021 May;155:1-9. (PMID: 33690015)
J Clin Oncol. 2022 Feb 20;40(6):586-597. (PMID: 34985920)
Diagn Pathol. 2014 Jan 14;9:3. (PMID: 24422905)
Oncoimmunology. 2018 Mar 6;7(7):e1438111. (PMID: 29900038)
Lung Cancer. 2020 Dec;150:159-163. (PMID: 33171404)
Onco Targets Ther. 2014 Apr 12;7:567-73. (PMID: 24748806)
J Thorac Oncol. 2017 May;12(5):878-883. (PMID: 28104537)
EClinicalMedicine. 2021 Jun 26;38:100990. (PMID: 34505024)
Nature. 2002 Jun 27;417(6892):949-54. (PMID: 12068308)
Cancer Immunol Immunother. 2017 Sep;66(9):1175-1187. (PMID: 28451792)
Ann Oncol. 2014 Oct;25(10):1935-1940. (PMID: 25009014)
Thorac Cancer. 2021 Sep;12(17):2339-2344. (PMID: 34291566)
Lung Cancer. 2019 Aug;134:174-179. (PMID: 31319978)
Cancer Res. 2007 Mar 15;67(6):2643-8. (PMID: 17363584)
Crit Rev Oncol Hematol. 1995 Jul;19(3):183-232. (PMID: 7612182)
J Cancer Res Clin Oncol. 2021 May;147(5):1547-1556. (PMID: 33196892)
Br J Cancer. 2015 Jan 6;112(1):95-102. (PMID: 25349974)
Front Oncol. 2021 Aug 23;11:703143. (PMID: 34497760)
Sci Rep. 2017 Apr 07;7:46209. (PMID: 28387300)
J Thorac Oncol. 2016 Nov;11(11):1879-1890. (PMID: 27346415)
J Thorac Oncol. 2020 Oct;15(10):1657-1669. (PMID: 32599071)
N Engl J Med. 2019 Nov 21;381(21):2020-2031. (PMID: 31562796)
Oncotarget. 2017 Apr 4;8(14):23517-23528. (PMID: 28423587)
Oncoimmunology. 2020 Jun 26;9(1):1781333. (PMID: 32923143)
N Engl J Med. 2018 May 31;378(22):2078-2092. (PMID: 29658856)
Neurooncol Adv. 2021 Nov 10;3(1):vdab166. (PMID: 34988451)
Pathol Oncol Res. 2021 Apr 08;27:597499. (PMID: 34257548)
Lung Cancer. 2017 Jan;103:44-51. (PMID: 28024695)
Proc Natl Acad Sci U S A. 1987 Dec;84(24):9270-4. (PMID: 2827175)
Cell Rep. 2017 May 9;19(6):1189-1201. (PMID: 28494868)
Oncotarget. 2015 Jun 10;6(16):14209-19. (PMID: 25895031)
J Thorac Oncol. 2018 Aug;13(8):1128-1137. (PMID: 29723688)
Immunity. 2017 Dec 19;47(6):1083-1099.e6. (PMID: 29246442)
Lung Cancer. 2019 Aug;134:79-84. (PMID: 31320000)
Int J Clin Exp Pathol. 2019 Mar 01;12(3):774-786. (PMID: 31933885)
Transl Lung Cancer Res. 2021 Jun;10(6):2937-2954. (PMID: 34295689)
Int Immunol. 2007 Mar;19(3):337-43. (PMID: 17267414)
Pathol Oncol Res. 2020 Jan;26(1):79-89. (PMID: 30225784)
J Thorac Dis. 2019 Nov;11(11):4591-4601. (PMID: 31903248)
Clin Cancer Res. 2019 Feb 1;25(3):1063-1069. (PMID: 30045933)
فهرسة مساهمة: Keywords: driver mutations; genomic alterations; immunohistochemistry (IHC); non‐small cell lung cancer (NSCLC); programmed death‐ligand 1 (PD‐L1)
المشرفين على المادة: EC 2.7.10.1 (Protein-Tyrosine Kinases)
0 (B7-H1 Antigen)
EC 2.7.10.1 (Anaplastic Lymphoma Kinase)
0 (Proto-Oncogene Proteins)
EC 2.7.10.1 (ErbB Receptors)
تواريخ الأحداث: Date Created: 20240308 Date Completed: 20240416 Latest Revision: 20240425
رمز التحديث: 20240425
مُعرف محوري في PubMed: PMC11016406
DOI: 10.1111/1759-7714.15244
PMID: 38456253
قاعدة البيانات: MEDLINE
الوصف
تدمد:1759-7714
DOI:10.1111/1759-7714.15244